According to Technavio, the global biomarkers market is expected to grow significantly from 2023 to 2027, with a CAGR of 13.05%. The increasing prevalence of cardiovascular diseases and the growing geriatric population are major factors driving this growth. The market is dominated by North America, which held the largest share in 2022 and is expected to continue its dominance throughout the forecast period.
Numerous companies are leveraging this growing market trend through strategic alliances, partnerships, mergers, and acquisitions. Key players in the cheese-based snacks market include Abbott Laboratories, Abcam plc, Agilent Technologies Inc., and Co., BG Medicine Inc., Bio Techne Corp., CENTOGENE NV, Charles River Laboratories International Inc., DiaSorin Spa, EKF Diagnostics Holdings Plc, Eurofins Scientific SE, F. Hoffmann La Roche Ltd., General Electric Co., Merck KGaA, Meso Scale Diagnostics LLC, Nexus Dx Inc., QIAGEN NV, Quest Diagnostics Inc., Siemens AG, and Thermo Fisher Scientific Inc.
The biomarkers market includes consumables, services, software, and molecular markers, such as natriuretic peptides and C-reactive protein. It also encompasses in vitro diagnostics, personalized medicines, and emerging economies. Contract research organizations and the biopharmaceutical sector are significant segments of the market. Companies specializing in biomarker research and development, such as Roche, Abbott, and Thermo Fisher Scientific, are major players.
The safety biomarkers segment in the neurological diseases market is expected to witness notable growth due to the increasing focus on successful treatment and healthcare infrastructure development. However, challenges exist in areas such as cancer, companion diagnostics, and infectious disease diagnosis due to high research investments in infrastructure, equipment, and skilled personnel. Sophisticated laboratory facilities and advanced technologies are essential for accurate biomarker assays.
Despite these challenges, continued research is necessary for fatal diseases like bowel cancer and smoking-related illnesses. Digital biomarkers are also emerging in various fields, with companies like Amgen, ImmunoGen, and Roche leading the way. Funds and grants, product innovations, and biomarker advancements are crucial for overcoming these challenges.
The Lancet, PLOS Journal, Nature Journal, and SSI Strategy are key publications for biomarker research. Efficacy, safety, and validation biomarkers are essential for disease risk assessment and diagnostics in various fields, including infectious diseases, neurological disorders, and immunological disorders. Consumables, services, software, and consumables are essential components of the biomarkers market.
The global biomarkers market is expanding due to increasing research and development programs and new product launches in the biopharmaceutical sector. Biomarkers play a crucial role in drug discovery and disease diagnosis, particularly in cancer. Early detection of cancer and other fatal diseases through non-invasive examinations is a major focus, with biomarkers enabling the identification of active genes and protein products indicative of a regular or cancerous state.
